Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
M Khamashta, JT Merrill, VP Werth, R Furie… - Annals of the rheumatic …, 2016 - Elsevier
Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb,
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with
moderate to severe active systemic lupus erythematosus (SLE). Methods 431 patients were
randomised and received monthly intravenous sifalimumab (200 mg, 600 mg or 1200 mg) or
placebo in addition to standard-of-care medications. Patients were stratified by disease
activity, interferon gene-signature test (high vs low based on the expression of four genes) …
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with
moderate to severe active systemic lupus erythematosus (SLE). Methods 431 patients were
randomised and received monthly intravenous sifalimumab (200 mg, 600 mg or 1200 mg) or
placebo in addition to standard-of-care medications. Patients were stratified by disease
activity, interferon gene-signature test (high vs low based on the expression of four genes) …